4.4 Article

Pain in adult patients with Pompe disease A cross-sectional survey

Journal

MOLECULAR GENETICS AND METABOLISM
Volume 109, Issue 4, Pages 371-376

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.ymgme.2013.05.021

Keywords

Pompe disease; Glycogen storage disease type 2; Acid maltase deficiency; Acid alpha-glucosidase; Lysosomal storage disorders; Pain

Funding

  1. Genzyme Corporation
  2. Sanofi Company
  3. ZonMw - The Netherlands Organisation for Health Research and Development [152001005]
  4. Dutch TI Pharma initiative Sustainable Orphan Drug Development through Registries and Monitoring [T6-208]
  5. EUCLYD - European Consortium for Lysosomal Storage Diseases [201678]
  6. Prinses Beatrix Fonds [OP07-08]
  7. Genzyme Corporation, Cambridge, MA, USA
  8. Erasmus MC

Ask authors/readers for more resources

Background: Pompe disease is a rare hereditary metabolic myopathy caused by a deficiency of acid-a-glucosidase. We investigated the presence and severity of pain and its interference with daily activities in a large group of adults with Pompe disease, who we compared with an age-matched control group. Methods: Data were collected in a cross-sectional survey in Germany and The Netherlands. Pain was assessed using the short-form brief pain inventory (BPI). Patients also completed the Short Form-36 item (SF-36v2), the Hospital Anxiety and Depression Scale (HADS) and the Rotterdam Handicap Scale (RHS). Results: Forty-five percent of the 124 adult Pompe patients reported having had pain in the previous 24 h, against 27% of the 111 controls (p = 0.004). The median pain severity score in Pompe patients reporting pain was 3.1 (on a scale from 0 to 10), indicating mild pain; against 2.6 amongst controls (p = 0.06). The median score of pain interference with daily activities in patients who reported pain was 3.3, against 1.3 in controls (p = 0.001). Relative to patients without pain, those with pain had lower RHS scores (p = 0.02), lower SF-36 Physical and Mental component summary scores (p < 0.001 and p = 0.049), and higher levels of depression and anxiety (p = 0.005 and p = 0.003). Conclusions: To date, this is one of the largest studies on pain in a specific neuromuscular disorder. Nearly one in two Pompe patients had experienced pain in the previous 24 h. Although pain severity and its interference with daily life were mild, pain was related to a reduced quality of life, less participation in daily life, and greater depression and anxiety. Its management should therefore be seen as part of clinical practice involving Pompe patients. (C) 2013 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available